NASDAQ · ABSI
Healthcare · Biotechnology
$9.04
Up+$0.33 (+3.79%)
Updated Sep 1, 2026, 10:19 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ABSI closed at $9.04 after 21 trading sessions, up 14.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $8.67 | $9.09 | $8.6198 | $9.04 | 5.26M |
| Aug 28, 2026 | $9.202 | $9.30 | $8.60 | $8.71 | 2.51M |
| Aug 27, 2026 | $9.28 | $9.6788 | $9.155 | $9.42 | 3.21M |
| Aug 26, 2026 | $9.555 | $9.65 | $8.90 | $9.22 | 2.68M |
| Aug 25, 2026 | $9.11 | $9.705 | $9.10 | $9.63 | 2.34M |
| Aug 24, 2026 | $9.33 | $9.36 | $8.75 | $8.84 | 2.2M |
| Aug 21, 2026 | $9.56 | $9.90 | $9.50 | $9.55 | 2.33M |
| Aug 20, 2026 | $9.74 | $10.03 | $9.24 | $9.28 | 2.91M |
| Aug 19, 2026 | $9.42 | $10.015 | $9.35 | $9.99 | 4.53M |
| Aug 18, 2026 | $8.87 | $9.14 | $8.55 | $8.85 | 2.48M |
| Aug 17, 2026 | $9.19 | $9.335 | $8.84 | $9.24 | 2.15M |
| Aug 14, 2026 | $9.43 | $9.435 | $8.83 | $9.18 | 2.23M |
| Aug 13, 2026 | $9.58 | $9.66 | $9.195 | $9.46 | 2.55M |
| Aug 12, 2026 | $9.02 | $9.67 | $8.64 | $9.50 | 4.04M |
| Aug 11, 2026 | $9.03 | $9.42 | $8.89 | $9.41 | 2.88M |
| Aug 10, 2026 | $9.00 | $9.47 | $8.90 | $9.01 | 2.97M |
| Aug 7, 2026 | $8.55 | $8.97 | $8.47 | $8.93 | 2.19M |
| Aug 6, 2026 | $8.22 | $8.55 | $8.13 | $8.30 | 1.77M |
| Aug 5, 2026 | $8.585 | $8.77 | $8.34 | $8.40 | 2.1M |
| Aug 4, 2026 | $8.20 | $8.585 | $8.198 | $8.48 | 1.98M |
| Aug 3, 2026 | $7.70 | $8.065 | $7.43 | $7.93 | 2.22M |
The latest Smart Investors Daily articles mentioning ABSI.
ABSI research
Company profile and research snapshot.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Needham | Buy | — |
| Aug 12, 2026 | BTIG | Buy | — |
| Jul 2, 2026 | Truist Securities | Buy | — |
| Jun 25, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 24, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.
Benzinga · Aug 12, 2026
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $11 price target.
Benzinga · Aug 12, 2026
BTIG analyst Kambiz Yazdi reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $13 price target.
SeekingAlpha · Aug 11, 2026
Absci Corporation (ABSI) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsAlexander Khan - CVP of Finance & Head of Investor...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABSI.
